Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,244 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2.
Sandborn WJ, Colombel JF, D'Haens G, Van Assche G, Wolf D, Kron M, Lazar A, Robinson AM, Yang M, Chao JD, Thakkar R. Sandborn WJ, et al. Among authors: chao jd. Aliment Pharmacol Ther. 2013 Jan;37(2):204-13. doi: 10.1111/apt.12145. Epub 2012 Nov 23. Aliment Pharmacol Ther. 2013. PMID: 23173821
Infliximab vs. Adalimumab for Crohn's disease.
Mulani P, Chao J. Mulani P, et al. Among authors: chao j. Aliment Pharmacol Ther. 2008 Nov 15;28(10):1265-6; author reply 1266-7. doi: 10.1111/j.1365-2036.2008.03829.x. Aliment Pharmacol Ther. 2008. PMID: 18959524 No abstract available.
The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy.
Lichtiger S, Binion DG, Wolf DC, Present DH, Bensimon AG, Wu E, Yu AP, Cardoso AT, Chao J, Mulani PM, Lomax KG, Kent JD. Lichtiger S, et al. Among authors: chao j. Aliment Pharmacol Ther. 2010 Nov;32(10):1228-39. doi: 10.1111/j.1365-2036.2010.04466.x. Epub 2010 Sep 28. Aliment Pharmacol Ther. 2010. PMID: 20955442 Clinical Trial.
Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial.
Panaccione R, Loftus EV Jr, Binion D, McHugh K, Alam S, Chen N, Guerette B, Mulani P, Chao J. Panaccione R, et al. Among authors: chao j. Can J Gastroenterol. 2011 Aug;25(8):419-25. doi: 10.1155/2011/724813. Can J Gastroenterol. 2011. PMID: 21912766 Free PMC article. Clinical Trial.
Adalimumab induces deep remission in patients with Crohn's disease.
Colombel JF, Rutgeerts PJ, Sandborn WJ, Yang M, Camez A, Pollack PF, Thakkar RB, Robinson AM, Chen N, Mulani PM, Chao J. Colombel JF, et al. Among authors: chao j. Clin Gastroenterol Hepatol. 2014 Mar;12(3):414-22.e5. doi: 10.1016/j.cgh.2013.06.019. Epub 2013 Jul 12. Clin Gastroenterol Hepatol. 2014. PMID: 23856361 Clinical Trial.
2,244 results